Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB-119 in healthy volunteers
NCT02084251Phase 1Completed
- Sponsor
- PegBio
- Start
- Feb 2014
- Primary completion
- Nov 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of visepegenatide in type 2 diabetes mellitus (T2DM), sponsored by PegBio. Started Feb 2014; status: completed.
02
Drugs
visepegenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02084251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02084251.